HT
KPTI icon

Headlands Technologies’s Karyopharm Therapeutics KPTI Stock Holding History

Headlands Technologies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-83
Closed -$1.88K – 1392
2024
Q1 		$1.88K Buy
+83
New +$1.46K ﹤0.01% 1168
2023
Q4 		– Sell
-921
Closed -$18.5K – 1134
2023
Q3 		$18.5K Buy
+921
New +$20.7K 0.01% 600

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Headlands Technologies's KPTI Position: Q2 2024 in Review

Headlands Technologies sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 83 shares — an estimated $1.88K sold.

Headlands Technologies first reported a position in KPTI in Q3 2023 and held it in 2 quarters. The position peaked at $18.5K in Q3 2023. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Headlands Technologies reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Headlands Technologies sold 83 Karyopharm Therapeutics shares in Q2 2024, an estimated $1.88K.
  • Headlands Technologies first reported a position in Karyopharm Therapeutics in Q3 2023 and held it in 2 quarters.
  • Headlands Technologies's Karyopharm Therapeutics position peaked at $18.5K in Q3 2023.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Headlands Technologies's 13F filing for Q2 2024, filed 7 Aug 2024.